BillionToOne, a Menlo Park, CA-based molecular diagnostics company, raised $125M in Series C funding.
The round was led by Adams Street Partners and Hummingbird Ventures with participation from Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital. Thomas Bremner from Adams Street Partners, is joining BillionToOne’s Board of Directors.
The company intend sto use the funds to expand the commercial and clinical teams, scale up lab capacity, and conduct clinical studies for their liquid biopsy test.
Co-founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D., BillionToOne is a molecular diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible. The company’s QCT molecular counter platform can count DNA molecules at the single-count level with single base-pair precision.
Its flagship product, UNITY Screen™, is an non-invasive prenatal test (NIPT) that can assess fetal risk for common recessive conditions and aneuploidies from one maternal blood sample. UNITY Screen™ does not require a paternal sample to assess fetal risk, supporting greater equity in care.
FinSMEs
31/03/2022